Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells
ImmunoHorizons · 01.01.2024 · 8 (1) · 97-105
DOI: 10.4049/immunohorizons.2300099 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoHorizons, online erschienen am 19.01.2024. Verfasst von Neha Diwanji und 2 weiteren Autor:innen. Beteiligte Einrichtung: Myeloid Therapeutics, Cambridge, MA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimeric Ag receptor (CAR) NK cells are challenging to manufacture and fail to achieve consistent tumor infiltration and sustained cytolytic function in the tumor microenvironment. In vivo engineering of NK cells using mRNA-based CAR delivery may overcome these issues. In this study, we developed an in vivo programming method by designing CARs that leverage the biology of NK cell receptors for cell type–specific expression and function. These CARs were engineered by fusion of a tumor recognition domain with the natural cytotoxic receptor family including NKp30, NKp44, and NKp46. Our results demonstrated that these natural cytotoxic receptor–based CARs can engage endogenous signaling adaptors to effectively activate human NK cells for tumor lysis and cytokine production. Specifically, we discovered that stable expression of an NKp44-based CAR was contingent on the presence of the immune cell–specific signaling adaptor DAP12. This innovative strategy facilitates direct in situ programming of NK cells, enhancing safety and minimizing off-target effects in nontargeted, healthy tissues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Myeloid Therapeutics, Cambridge, MA.
ORCID-Profile: Neha Diwanji
Zitieren
APA
Diwanji, N., Getts, D., & Wang, Y. (2024). Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells. ImmunoHorizons, 8(1), 97-105. https://doi.org/10.4049/immunohorizons.2300099
Vancouver
Diwanji N, Getts D, Wang Y. Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells. ImmunoHorizons. 2024;8(1):97-105. doi:10.4049/immunohorizons.2300099
BibTeX
@article{Diwanji2024,
author = {Diwanji, Neha and Getts, Daniel and Wang, Yuxiao},
title = {Chimeric Antigen Cytotoxic Receptors for In Vivo Engineering of Tumor-Targeting NK Cells},
journal = {ImmunoHorizons},
year = {2024},
volume = {8},
number = {1},
pages = {97--105},
doi = {10.4049/immunohorizons.2300099}
}
EUVIMED